MedPath

Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment

Not Applicable
Completed
Conditions
Sleep Apnea
Interventions
Other: Standard care for OSA
Device: CPAP
Registration Number
NCT01826032
Lead Sponsor
Hospital Clinic of Barcelona
Brief Summary

In the near future more than 20% of the European population will be over 65 years old and the prevalence of obstructive sleep apnea (OSA) in this aged population is known to be higher than 50%. OSA is a risk factor for cognitive dysfunction in middle-aged subjects, but the relationship between cognitive impairment and sleep breathing disorders (SBD) in the elderly has scarcely been observed.

The aim of this study is to investigate cognitive performance in elderly OSA patients, the corresponding brain morphology changes and biological markers and their reversibility with continuous positive airway pressure (CPAP) treatment.

Detailed Description

Patients: We will include consecutive patients with a diagnosis of severe OSA (AHI\> 30) without significant comorbidities or excessive daytime sleepiness (Epworth ≤ 12). Patients will be randomized to CPAP treatment or conservative treatment.

Methodology: We will assess at baseline and after 3 months of treatment:

1. Neuroimaging by MRI

2. Neurocognitive function with an extensive neuropsychological battery assessing principally memory, attention and executive functions (Trail-making test A and B, Rey Auditory Verbal Learning Test, Digit span, Digit symbol),

3. Biological markers of inflammation and endothelial dysfunction.

Patients included in the study will be monitored and followed for three months. They will be examined at the time of inclusion, after two and six weeks and at the end (12 weeks) for clinical monitoring and the evaluation of adaptation to treatment and compliance.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
33
Inclusion Criteria
  1. Men and women ≥ 65 years old.
  2. Patients diagnosed with OSA with an apnea-hypopnea index per hour >30.
  3. Patients with an Epworth Sleep Scale score ≤ 12 (without excessive daytime sleepiness).
  4. Signed written informed consent.
Exclusion Criteria
  1. Patients with severe chronic diseases: cardiovascular or pulmonary, neurological (stroke, epilepsy, head injury...) or psychiatric.
  2. Any current significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol or may, in the opinion of the investigator, compromise the conclusions.
  3. Mini Mental State Exam (MMSE) <24.
  4. Any MRI exclusions - presence of aneurysm clips, pacemakers, mechanic heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
  5. Previous CPAP treatment.
  6. Psycho-physical inability to complete questionnaires. Inadequate visual and auditory acuity will be excluded.
  7. Presence of any previously diagnosed sleep disorders: narcolepsy, insomnia, chronic sleep deprivation, REM behavior disorder and restless leg syndrome.
  8. Patients with > 50% of central apneas or the presence of Cheyne-Stokes Respiration.
  9. History of alcohol abuse or dependence.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard care for OSAStandard care for OSASleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
CPAPCPAPPatients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure. This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling.
CPAPStandard care for OSAPatients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure. This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling.
Primary Outcome Measures
NameTimeMethod
Structural and functional brain changesat baseline and after 3 months of treatment
Secondary Outcome Measures
NameTimeMethod
Assessment of the changing of the neuropsychological tests.at baseline and after 3 months of treatment
OSA symptoms (daytime sleepiness and everyday function) and quality of lifeat baseline and after 3 months of treatment

Trial Locations

Locations (1)

Hospital Clinic Barcelona

🇪🇸

Barcelona, Catalonia, Spain

© Copyright 2025. All Rights Reserved by MedPath